1. Home
  2. SACH vs ACRV Comparison

SACH vs ACRV Comparison

Compare SACH & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sachem Capital Corp.

SACH

Sachem Capital Corp.

HOLD

Current Price

$0.80

Market Cap

38.4M

Sector

Real Estate

ML Signal

HOLD

Logo Acrivon Therapeutics Inc.

ACRV

Acrivon Therapeutics Inc.

HOLD

Current Price

$1.62

Market Cap

68.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SACH
ACRV
Founded
2010
2018
Country
United States
United States
Employees
27
76
Industry
Real Estate Investment Trusts
Medicinal Chemicals and Botanical Products
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
38.4M
68.5M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
SACH
ACRV
Price
$0.80
$1.62
Analyst Decision
Buy
Buy
Analyst Count
2
4
Target Price
$2.00
$11.67
AVG Volume (30 Days)
133.3K
449.4K
Earning Date
05-06-2026
05-08-2026
Dividend Yield
19.23%
N/A
EPS Growth
N/A
15.13
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$145.00
N/A
Revenue Next Year
$6.80
$568.17
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.80
$1.20
52 Week High
$1.45
$3.56

Technical Indicators

Market Signals
Indicator
SACH
ACRV
Relative Strength Index (RSI) 26.77 41.17
Support Level N/A $1.38
Resistance Level $1.12 $2.15
Average True Range (ATR) 0.03 0.14
MACD -0.00 -0.04
Stochastic Oscillator 1.87 2.70

Price Performance

Historical Comparison
SACH
ACRV

About SACH Sachem Capital Corp.

Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns the majority of its revenue through Interest income from loans.

About ACRV Acrivon Therapeutics Inc.

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.

Share on Social Networks: